Search｜Photos & Images & Videos｜KYODO NEWS IMAGES INC

Robot Mall in Beijing

BEIJING, CHINA - AUGUST 9, 2025 - A smart pharmacy robot retrieves medication for "patients" at Robot Mall, the world's first Embodied Intelligence robot 4S store in Beijing, China on August 9, 2025.

E

Warning Issued Over Popular Weight-Loss Drugs - The Hague

Weight-loss medication such as Ozempic and wegovy are captured in a pharmacy in The Hague, Netherlands on July 4, 2025. Nutrition Center warns of consequences of slimming medication. The Nutrition Center warns people who want to lose weight not to take the use of medication too lightly. Drugs such as Ozempic, injection medication that helps people lose a lot of weight quickly, are becoming increasingly popular. Photo by Robin Utrecht/ABACAPRESS.COM

E

Warning Issued Over Popular Weight-Loss Drugs - The Hague

Weight-loss medication such as Ozempic and wegovy are captured in a pharmacy in The Hague, Netherlands on July 4, 2025. Nutrition Center warns of consequences of slimming medication. The Nutrition Center warns people who want to lose weight not to take the use of medication too lightly. Drugs such as Ozempic, injection medication that helps people lose a lot of weight quickly, are becoming increasingly popular. Photo by Robin Utrecht/ABACAPRESS.COM

E

Warning Issued Over Popular Weight-Loss Drugs - The Hague

Weight-loss medication such as Ozempic and wegovy are captured in a pharmacy in The Hague, Netherlands on July 4, 2025. Nutrition Center warns of consequences of slimming medication. The Nutrition Center warns people who want to lose weight not to take the use of medication too lightly. Drugs such as Ozempic, injection medication that helps people lose a lot of weight quickly, are becoming increasingly popular. Photo by Robin Utrecht/ABACAPRESS.COM

E

Warning Issued Over Popular Weight-Loss Drugs - The Hague

Weight-loss medication such as Ozempic and wegovy are captured in a pharmacy in The Hague, Netherlands on July 4, 2025. Nutrition Center warns of consequences of slimming medication. The Nutrition Center warns people who want to lose weight not to take the use of medication too lightly. Drugs such as Ozempic, injection medication that helps people lose a lot of weight quickly, are becoming increasingly popular. Photo by Robin Utrecht/ABACAPRESS.COM

E

Warning Issued Over Popular Weight-Loss Drugs - The Hague

Weight-loss medication such as Ozempic and wegovy are captured in a pharmacy in The Hague, Netherlands on July 4, 2025. Nutrition Center warns of consequences of slimming medication. The Nutrition Center warns people who want to lose weight not to take the use of medication too lightly. Drugs such as Ozempic, injection medication that helps people lose a lot of weight quickly, are becoming increasingly popular. Photo by Robin Utrecht/ABACAPRESS.COM

E

Warning Issued Over Popular Weight-Loss Drugs - The Hague

Weight-loss medication such as Ozempic and wegovy are captured in a pharmacy in The Hague, Netherlands on July 4, 2025. Nutrition Center warns of consequences of slimming medication. The Nutrition Center warns people who want to lose weight not to take the use of medication too lightly. Drugs such as Ozempic, injection medication that helps people lose a lot of weight quickly, are becoming increasingly popular. Photo by Robin Utrecht/ABACAPRESS.COM

E

Warning Issued Over Popular Weight-Loss Drugs - The Hague

Weight-loss medication such as Ozempic and wegovy are captured in a pharmacy in The Hague, Netherlands on July 4, 2025. Nutrition Center warns of consequences of slimming medication. The Nutrition Center warns people who want to lose weight not to take the use of medication too lightly. Drugs such as Ozempic, injection medication that helps people lose a lot of weight quickly, are becoming increasingly popular. Photo by Robin Utrecht/ABACAPRESS.COM

E

Warning Issued Over Popular Weight-Loss Drugs - The Hague

Weight-loss medication such as Ozempic and wegovy are captured in a pharmacy in The Hague, Netherlands on July 4, 2025. Nutrition Center warns of consequences of slimming medication. The Nutrition Center warns people who want to lose weight not to take the use of medication too lightly. Drugs such as Ozempic, injection medication that helps people lose a lot of weight quickly, are becoming increasingly popular. Photo by Robin Utrecht/ABACAPRESS.COM

E

Warning Issued Over Popular Weight-Loss Drugs - The Hague

Weight-loss medication such as Ozempic and wegovy are captured in a pharmacy in The Hague, Netherlands on July 4, 2025. Nutrition Center warns of consequences of slimming medication. The Nutrition Center warns people who want to lose weight not to take the use of medication too lightly. Drugs such as Ozempic, injection medication that helps people lose a lot of weight quickly, are becoming increasingly popular. Photo by Robin Utrecht/ABACAPRESS.COM

E

Warning Issued Over Popular Weight-Loss Drugs - The Hague

Weight-loss medication such as Ozempic and wegovy are captured in a pharmacy in The Hague, Netherlands on July 4, 2025. Nutrition Center warns of consequences of slimming medication. The Nutrition Center warns people who want to lose weight not to take the use of medication too lightly. Drugs such as Ozempic, injection medication that helps people lose a lot of weight quickly, are becoming increasingly popular. Photo by Robin Utrecht/ABACAPRESS.COM

E

Warning Issued Over Popular Weight-Loss Drugs - The Hague

Weight-loss medication such as Ozempic and wegovy are captured in a pharmacy in The Hague, Netherlands on July 4, 2025. Nutrition Center warns of consequences of slimming medication. The Nutrition Center warns people who want to lose weight not to take the use of medication too lightly. Drugs such as Ozempic, injection medication that helps people lose a lot of weight quickly, are becoming increasingly popular. Photo by Robin Utrecht/ABACAPRESS.COM

E

Warning Issued Over Popular Weight-Loss Drugs - The Hague

Weight-loss medication such as Ozempic and wegovy are captured in a pharmacy in The Hague, Netherlands on July 4, 2025. Nutrition Center warns of consequences of slimming medication. The Nutrition Center warns people who want to lose weight not to take the use of medication too lightly. Drugs such as Ozempic, injection medication that helps people lose a lot of weight quickly, are becoming increasingly popular. Photo by Robin Utrecht/ABACAPRESS.COM

E

Warning Issued Over Popular Weight-Loss Drugs - The Hague

Weight-loss medication such as Ozempic and wegovy are captured in a pharmacy in The Hague, Netherlands on July 4, 2025. Nutrition Center warns of consequences of slimming medication. The Nutrition Center warns people who want to lose weight not to take the use of medication too lightly. Drugs such as Ozempic, injection medication that helps people lose a lot of weight quickly, are becoming increasingly popular. Photo by Robin Utrecht/ABACAPRESS.COM

E

Warning Issued Over Popular Weight-Loss Drugs - The Hague

Weight-loss medication such as Ozempic and wegovy are captured in a pharmacy in The Hague, Netherlands on July 4, 2025. Nutrition Center warns of consequences of slimming medication. The Nutrition Center warns people who want to lose weight not to take the use of medication too lightly. Drugs such as Ozempic, injection medication that helps people lose a lot of weight quickly, are becoming increasingly popular. Photo by Robin Utrecht/ABACAPRESS.COM

E

Surgical unit of underground hospital

Blood bags and medications are kept in a refrigerator in a surgical unit of an underground hospital in an area of hostilities on April 15, 2025. (Photo by Dmytro Smolienko/Ukrinform)

E

Ethiopia Tigray in Crisis

Debretsion Gebremichael, Ethiopia’s ex-deputy prime minister and leader of the TPLF (Tigray People's Liberation Front), poses for the camera in his office in Mekele, Ethiopia on April 13, 2025. Following the suspension of USAID and sweeping aid cuts under the Trump administration, food distributions in IDP camps like 70 Kare have fallen from 15 to just 9 kilograms per person, while soaring medication costs have left Tigray’s displaced communities increasingly vulnerable and underserved. Photo by Middle East Images/ABACAPRESS.COM

E

Ethiopia Tigray in Crisis

Tigist, 40, speaks from her bed at an IDP centre in Mekele, Ethiopia on March 27, 2025. Forced to flee her home in Humera in 2020, she now suffers from kidney disease and cannot afford the 700 birr (€4.95) monthly medication. “I wouldn’t ask Trump for aid, just to help me return home,” she says. Photo by Middle East Images/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

CGT Union Protests Sanofi - Lisieux

A photo shows flags of the CGT union at the entrance of the Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

E

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM